Jeffrey D. Kent, M.D., FACG, FACP, joined Horizon in May 2012. Prior to Horizon, Dr. Kent was executive director, medical affairs at Astellas Pharmaceuticals. Prior to Astellas, he spent over 8 years as global project head for medical affairs in immunology within Abbott Global Pharmaceutical research and development. In this capacity, he had global medical affairs responsibility for HUMIRA across the rheumatology, dermatology, and gastroenterology therapeutic areas. Dr. Kent also worked at Searle (now Pfizer) from 1999 to 2003, and served in various capacities in research and development including global director for valdecoxib (Bextra) development. Dr. Kent is a graduate of Franklin and Marshall College and the Jefferson Medical College in Philadelphia where he received his M.D. degree. He completed a residency in Internal Medicine at Thomas Jefferson University Hospital and a fellowship in gastroenterology and hepatology at Rush Presbyterian St. Luke's Hospital in Chicago. He served as a full-time faculty member for several years in the Department of Internal Medicine and the Division of Digestive Diseases at Rush Medical College and Rush Presbyterian St. Luke's Hospital. While at Rush, Dr. Kent was heavily involved with clinical practice, educating medical students, residents, and fellows, and developed extensive experience with Phase 2-4 clinical trials. Following his experience at Rush, he served as Associate Medical Director for the Evanston Hospital Clinical Pharmacology Unit, a Phase 1 clinical trials facility and gained experience with first-in-man and ADME studies.

Source: Horizon Therapeutics Public Limited Company on 01/04/2021